No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 100, Issue 12, 2006, Pages 1098-1104

  McCall, Matthew B B ^a   Beynon, Andy J ^a   Mylanus, Emmanuel A M ^a   van der Ven, Andre J A M ^a   Sauerwein, Robert W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Artemether lumefantrine; Artemisinin; Hearing loss; Malaria; Neurotoxicity

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL;

ADULT; ARTICLE; AUDITORY SYSTEM EXAMINATION; CLINICAL ARTICLE; DISEASE COURSE; DRUG USE; EVOKED BRAIN STEM AUDITORY RESPONSE; EXPERIMENTAL INFECTION; FEMALE; HEARING LOSS; HEARING TEST; HUMAN; MALARIA; MALE; PURE TONE AUDIOMETRY; STATISTICAL ANALYSIS; VOLUNTEER;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; AUDIOMETRY, PURE-TONE; DRUG COMBINATIONS; ETHANOLAMINES; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; FLUORENES; HEARING LOSS; HUMANS; MALARIA, FALCIPARUM; MALE;

ANIMALIA;

EID: 33749040663     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.02.017     Document Type: Article

References (21)

1. Atherley G.R., and Dingwall-Fordyce I. The reliability of repeated auditory threshold determination. Br. J. Ind. Med. 20 (1963) 231-235
2. Brewer T.G., Grate S.J., Peggins J.O., Weina P.J., Petras J.M., Levine B.S., Heiffer M.H., and Schuster B.G. Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg. 51 (1994) 251-259
3. Frank T. High-frequency (8 to 16 kHz) reference thresholds and intrasubject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. Ear Hear. 22 (2001) 161-168
4. Genovese R.F., Nguyen H.A., and Mog S.R. Effects of arteether on an auditory radial-arm maze task in rats. Physiol. Behav. 73 (2001) 87-91
5. Gordi T., and Lepist E.I. Artemisinin derivatives: toxic for laboratory animals, safe for humans?. Toxicol. Lett. 147 (2004) 99-107
6. Jewett D.L., and Williston J.S. Auditory-evoked far fields averaged from the scalp of humans. Brain 94 (1971) 681-696
7. Kissinger E., Hien T.T., Hung N.T., Nam N.D., Tuyen N.L., Dinh B.V., Mann C., Phu N.H., Loc P.P., Simpson J.A., White N.J., and Farrar J.J. Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. Am. J. Trop. Med. Hyg. 63 (2000) 48-55
8. Kremsner P.G., and Krishna S. Antimalarial combinations. Lancet 364 (2004) 285-294
9. Miller L.G., and Panosian C.B. Ataxia and slurred speech after artesunate treatment for falciparum malaria. New Engl. J. Med. 336 (1997) 1328
10. Nontprasert A., Pukrittayakamee S., Dondorp A.M., Clemens R., Looareesuwan S., and White N.J. Neuropathologic toxicity of artemisinin derivatives in a mouse model. Am. J. Trop. Med. Hyg. 67 (2002) 423-429
11. Olliaro P.L., and Taylor W.R. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: a review. J. Postgrad. Med. 50 (2004) 40-44
12. Panossian L.A., Garga N.I., and Pelletier D. Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann. Neurol. 58 (2005) 812-813
13. Petras J.M., Young G.D., Bauman R.A., Kyle D.E., Gettayacamin M., Webster H.K., Corcoran K.D., Peggins J.O., Vane M.A., and Brewer T.G. Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. Anat. Embryol. 201 (2000) 383-397
14. Price R., van Vugt M., Phaipun L., Luxemburger C., Simpson J., McGready R., ter Kuile F., Kham A., Chongsuphajaisiddhi T., White N.J., and Nosten F. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am. J. Trop. Med. Hyg. 60 (1999) 547-555
15. Ribeiro I.R., and Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med. Trop. (Mars) 58 (1998) 50-53
16. Schneider P., Wolters L., Schoone G., Schallig H., Sillekens P., Hermsen R., and Sauerwein R. Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J. Clin. Microbiol. 43 (2005) 402-405
17. Skelton-Stroud P., and Mull R. Positioning, labelling, and medical information control of co-artemether tablets (CPG 56697): a fixed novel combination of artemether and benflumetol. Novartis Co-Artemether International Development Team. Med. Trop. (Mars) 58 (1998) 77-81
18. Toovey S., and Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans. R. Soc. Trop. Med. Hyg. 98 (2004) 261-267 discussion 268-269
19. Van Vugt M., Angus B.J., Price R.N., Mann C., Simpson J.A., Poletto C., Htoo S.E., Looareesuwan S., White N.J., and Nosten F. A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 62 (2000) 65-69
20. Verhage D.F., Telgt D.S., Bousema J.T., Hermsen C.C., van Gemert G.J., van der Meer J.W., and Sauerwein R.W. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth. J. Med. 63 (2005) 52-58
21. White N.J., van Vugt M., and Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37 (1999) 105-125